BioNTech SE and Pfizer Inc. said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults. The companies said data from a Phase 2/3 clinical trial yielded no new safety concerns when children in this age group received a booster six months after completing the primary series of shots. So far this year, BioNTech’s stock has tumbled 43.6% and Pfizer shares are down 16.9%, while the S&P 500 has declined 12.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
